Fostamatinib Production Cost Reports

The report provides detailed analysis essential for establishing a fostamatinib production plant. It encompasses all critical aspects necessary for fostamatinib production, including the cost of fostamatinib production, fostamatinib plant cost, fostamatinib production costs, and the overall fostamatinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a fostamatinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Fostamatinib Market Analysis: Demand and Supply Analysis, and Sourcing

Fostamatinib is an oral inhibitor of spleen tyrosine kinase, usually shortened to SYK. It is a phosphate prodrug, which means it is not active as swallowed. The chemistry was chosen to solve a solubility problem. Alkaline phosphatase in the gut strips off the phosphate group, releasing R406, the molecule that actually blocks the kinase. Blocking SYK interrupts Fc gamma receptor signaling in macrophages, which is how those cells recognize, bind, and destroy antibody-coated platelets. Rigel Pharmaceuticals developed it, won the first US approval for a SYK inhibitor, and sells it as Tavalisse there. Grifols sells it as Tavlesse across Europe, Turkey, the Middle East, North Africa, Russia, and the surrounding region.

Demand for fostamatinib is currently limited but growing. It is approved for adults with chronic immune thrombocytopenia who did not respond well to previous treatment. Patients usually start with 100 mg twice daily, with or without food. If their platelet count remains below the target after about four weeks, the dose can be increased to 150 mg twice daily. Treatment is stopped after twelve weeks if the platelet count does not improve enough to help prevent serious bleeding. This limits the amount of medicine used in patients who do not respond. A patient taking the higher dose uses about 110 g of the free acid or 138 g of the salt each year. Rigel reported Tavalisse sales of about USD 159 million last year, up 52%, supported by an increase in both patient numbers and average doses. Ongoing studies in warm autoimmune hemolytic anemia, IgA nephropathy, and other immune conditions could expand its use. Approval for these additional conditions could significantly increase demand.

Supply is held by one originator and its partners. Rigel has the product made for it by Patheon, at Whitby, in Ontario, Canada. Grifols distributes it in its own territories under license, paying tiered royalties. US patents stretch to 2032 on formulation claims, to 2031 on prodrug claims, and to 2030 on granulation claims. Several generic applications have reportedly been filed, though no filer, date, or launch plan is named publicly. A fostamatinib demand and supply analysis has to weigh immune thrombocytopenia patient numbers, the pace of label expansion, patent dates, and how few makers handle this phosphate prodrug chemistry. Few buyers exist outside the originator chain.

Summary of the Product, Grades, and Uses

Fostamatinib disodium hexahydrate has the molecular formula C23H24FN6Na2O9P·6H2O, a molar mass of 732.52 g/mol, and the CAS number 914295-16-2. The free acid has the CAS number 901119-35-5, while the anhydrous disodium salt has the CAS number 1025687-58-4. Its chemical structure contains a fluoropyrimidine, a trimethoxyaniline group, and a pyrido-oxazinone group, along with a phosphate group attached through a methylene linker. The drug substance is a white to off-white powder that flows easily. It dissolves poorly in acidic conditions, slightly in water, and well in methanol. Doses on the product label are expressed as free acid, so a 100 mg tablet contains 126.2 mg of the hexahydrate salt. This difference must be considered when calculating tablet production costs.

Fostamatinib is sold in two working grades, since no other market exists for it. Pharmaceutical API grade is the hexahydrate disodium salt, made under GMP for tablet manufacture, tested against tight specifications, and filed through drug master files. Reference and research grades cover the salt, the free acid, and the active metabolite R406, which research suppliers list separately for kinase studies.

Each lot is tested for assay, related substances, water content, sodium, phosphorus, residual solvents, and crystal form. Water content matters more than usual, because the hexahydrate must hold exactly six waters, no more and no fewer. Drying conditions are therefore specified tightly. Tablets come in 100 mg and 150 mg strengths, both orange, biconvex, and film-coated. Excipients include mannitol, sodium bicarbonate, sodium starch glycolate, povidone, and magnesium stearate. Bottles ship with two desiccant canisters, which buyers must leave in place. Moisture is the main enemy of this salt.

Main End-Uses of Fostamatinib

Chronic immune thrombocytopenia is the main use of fostamatinib. It is supplied through hematology clinics, specialty pharmacies, and hospitals. Doctors prescribe it when treatments such as steroids, immunoglobulin, spleen removal, and thrombopoietin receptor agonists have failed or stopped working. Unlike these treatments, fostamatinib reduces platelet destruction in the spleen and liver instead of increasing platelet production in the bone marrow. This makes it useful for patients who have not responded to other treatments. Having a different way of working gives hematologists another treatment option. Patients who respond may continue treatment for a long time, creating a steady demand for the drug. Increasing the dose from 100 mg to 150 mg raises API use by 50%, which must be considered when planning supplies.

Investigational immune disease is the second end-use for fostamatinib, in clinical trial supply and compassionate programs. Warm autoimmune hemolytic anemia has drawn the most attention, since the same macrophage pathway, the same receptors, and the same kinase destroy red cells there. Trials have also covered IgA nephropathy, rheumatoid arthritis, lymphoma, and severe respiratory illness. An earlier rheumatoid arthritis program did not deliver enough benefit in patients who had already failed a biologic. That setback reshaped the development plan. Trial supply needs the same GMP material, documentation, release testing, and stability data as commercial stock.

Research and analytical use completes demand for fostamatinib. Kinase biologists buy the prodrug and R406 to study SYK signaling in platelets, B cells, mast cells, and macrophages. Generic developers buy reference material and impurity standards for method validation. Analytical labs need standards for plasma assays, since the prodrug and metabolite must be measured separately. Both appear in pharmacokinetic reports. Such buyers order milligrams, usually once, with certificates, spectra, and full documentation.

Fostamatinib Market Risks

Fostamatinib faces competition, side effect concerns, and patent risks. Thrombopoietin receptor agonists such as eltrombopag, romiplostim, and avatrombopag account for much of the second-line market and have been used for longer. Newer treatments, including other SYK inhibitors, BTK inhibitors, and complement blockers, are also being tested for the same patients. Fostamatinib carries warnings about high blood pressure, liver injury, diarrhea, low neutrophil counts, and possible harm to an unborn baby. A hypertensive crisis occurred in 1% of patients, raised liver enzyme levels in 9%, and diarrhea in 31%. Patients need regular checks of blood pressure, liver function, and neutrophil counts, adding to the workload for clinics. Some patients stop treatment because of these monitoring needs. Once the patents expire, generic versions are likely to lower prices sharply, as seen with other medicines used to treat rare conditions.

Fostamatinib manufacturing faces challenges related to the phosphate group, water content, protecting groups, and product purity. The phosphate group is essential to the molecule but can also break down and form R406 during processing or storage. Production involves adding a protected phosphate reagent, controlling the heating process, and removing the tert-butyl groups without damaging the phosphate ester. The hexahydrate must be crystallized with the correct amount of water and protected from both drying and excess moisture. Impurities such as residual R406, des-phospho compounds, acetic acid solvate, and over-alkylated products must be carefully controlled. Batches may fail quality checks because of incorrect water content, impurities, changes in crystal form, or residual solvents. Correcting a batch with the wrong water content is often difficult.

Fostamatinib Production Process and Main Cost Drivers

The fostamatinib production process runs from 5-fluorouracil and amine building blocks through chlorination, two sequential displacements to R406, phosphate alkylation, deprotection, disodium salt formation, hexahydrate crystallization, drying, and packing under controlled humidity.

1. By Phosphate Prodrug Formation from the SYK Inhibitor R406: The main inputs are 5-fluorouracil, phosphoryl chloride, a pyrido-oxazinone amine, 3,4,5-trimethoxyaniline, di-tert-butyl chloromethyl phosphate, a base, acetic acid, sodium hydroxide or sodium alkoxide, alcohols, acetone, and purified water.

Fostamatinib production builds the active molecule first, then converts it to the prodrug. Rigel's published large-scale route starts by treating 5-fluorouracil with phosphoryl chloride to give 2,4-dichloro-5-fluoropyrimidine. One equivalent of the pyrido-oxazinone amine then displaces the more reactive chlorine, and the reaction is regioselective enough to avoid a mixture. The second chlorine is displaced by 3,4,5-trimethoxyaniline, which completes the diaminopyrimidine core and gives R406, the active metabolite also called tamatinib.

The prodrug is made after R406 has been synthesized. This second stage is the more difficult part of the process because phosphate reactions can be hard to scale up. R406 reacts with di-tert-butyl chloromethyl phosphate, which attaches the protected phosphate group to the oxazinone nitrogen through a methylene bridge. Heating the mixture in acetic acid removes both tert-butyl groups and produces the free phosphonic acid, which is collected as an acetic acid solvate. Adding two equivalents of a sodium base converts it into the disodium salt. The salt is then crystallized from a mixture of water and alcohol to form the hexahydrate. Temperature, water content, and seed crystals must be carefully controlled to obtain the approved crystal form. Drying must also be controlled, as excessive drying removes water from the hydrate, while insufficient drying leaves residual solvent. The solid is then lightly milled, sieved, tested, and packed under controlled humidity. The main factors affecting conversion costs are R406 yield, phosphate reagent cost, control of the deprotection step, and hydrate crystallization.

Main Factors Affecting Fostamatinib Production Cost

Fostamatinib production cost is shaped mainly by R406 and the phosphate step. By stoichiometry, each kilogram of the hexahydrate salt needs about 0.64 kg of R406, which in turn needs about 0.18 kg of 5-fluorouracil, and 0.25 kg of 3,4,5-trimethoxyaniline. The phosphate alkylation calls for about 0.35 kg of di-tert-butyl chloromethyl phosphate in theory. Real use runs higher, since every step loses material and the alkylation often needs excess reagent. The pyrido-oxazinone amine is a specialty intermediate made for this molecule alone, so it carries a high price.

The remaining costs come from product losses, water content control, testing, and humidity management. Each step after the trimethoxyaniline coupling adds to the cost of the earlier steps. The acetic acid deprotection stage needs close monitoring because prolonged heating, high temperatures, or wet solvents can break the phosphate ester formed earlier. Quality checks include HPLC testing for assay and impurities, Karl Fischer testing for water content, sodium and phosphorus measurements, X-ray diffraction to confirm the crystal form, and residual solvent testing. Areas with controlled humidity also increase equipment and operating costs, and few small plants already have these facilities. Upgrading existing plants can be expensive. Annual demand may be only a few tonnes worldwide, so fixed costs, overheads, and equipment depreciation are spread across a small production volume. Production volumes are likely to increase only when generic versions enter the market. Until then, output is expected to remain low.

Raw Materials for Fostamatinib Production Plant and its Procurement

Raw material sourcing for fostamatinib mainly involves the pyrido-oxazinone amine, trimethoxyaniline, and phosphate reagent. 5-Fluorouracil is a widely available oncology API produced in China and India at relatively low cost. 3,4,5-Trimethoxyaniline is supplied by fine chemical manufacturers in China, India, and Europe for use in the pharmaceutical and dye industries. The pyrido-oxazinone amine is usually made to order from a hydroxypyridine through amide formation, cyclization, and reduction. Di-tert-butyl chloromethyl phosphate is supplied by a small number of companies that specialize in phosphorus chemistry. Other inputs, including phosphoryl chloride, bases, acetic acid, alcohols, and acetone, are common industrial chemicals.

Raw material quality affects production yield, impurity levels, and crystal form. The oxazinone amine must contain low levels of unwanted isomers, ring-opened compounds, residual metals, and color impurities. 3,4,5-Trimethoxyaniline can react with air, so it is shipped under nitrogen and tested on arrival. The phosphate reagent reacts with moisture and must be stored in a cool, dry place. Its drums are kept sealed under nitrogen. Supplier contracts specify limits for purity, water content, color, related substances, and residual metals. Each batch is sampled, tested, recorded, and kept separate until quality checks are complete. Suppliers are audited before approval. Having a second supplier for the oxazinone amine helps prevent production delays.

Sustainability and Regulatory Requirements

Fostamatinib manufacture raises environmental duties around phosphorus waste, chlorinated reagents, and solvent use. Phosphoryl chloride releases hydrogen chloride and phosphoric acid on quenching, so vents need scrubbing and liquors need neutralization. Phosphate-rich wastewater must be collected, neutralized, and treated before discharge to avoid nutrient loading. Spent acetic acid from the deprotection step can be recovered by distillation, dried, tested, and reused. Tert-butyl groups removed in that step leave isobutylene, which needs venting through a thermal oxidizer. Solvent recovery for alcohols and acetone lowers both waste and cost. Recovery rates are usually high.

Regulatory duties for fostamatinib follow its status as a prescription small-molecule drug. API makers file US drug master files, and the finished product holds a new drug application in the US and a marketing authorization in the EU. Plants follow ICH Q7 for API, ICH Q3A, Q3C, and Q3D for impurities, solvents, and elemental impurities, and ICH M7 for mutagenic impurities. The hexahydrate form is specified, so regulators expect full solid-state data and stability under varied humidity. Labels require blood pressure, liver function, and neutrophil monitoring, plus contraception during treatment and for a month after. Orphan designation applied to the original US approval.

CAPEX and OPEX for a Fostamatinib Production Plant

A fostamatinib plant is a multi-step API unit with corrosion-resistant equipment, humidity control, and solvent recovery. The fostamatinib plant setup cost begins with glass-lined reactors for the phosphoryl chloride chlorination, which attacks ordinary steel. Stainless and glass-lined vessels serve the two displacement steps: the alkylation and the deprotection. Crystallizers with tight temperature and water control set the hexahydrate. Filters, centrifuges, and gentle vacuum dryers handle isolation without stripping hydrate water. Milling, sieving, weighing, and packing all happen in humidity-controlled rooms. Utilities cover chilled brine, steam, nitrogen, vacuum, scrubbers, and solvent recovery. On the QC side, the lab holds HPLC, LC-MS, Karl Fischer, X-ray diffraction, thermal analysis, and ICP for sodium and phosphorus.

Fostamatinib operating cost is driven by the oxazinone amine, the phosphate reagent, solvents, and labor. Acetic acid, bases, filter media, and packaging add steady variable costs. Energy goes mainly to distillation, drying, chilling, and humidity control. Fixed costs cover depreciation, validation, quality systems, insurance, and stability programs. Sharing the plant with other small-volume APIs brings the cost per kilogram down. Most contract makers work this way. Long campaigns also cut changeover, cleaning, and validation time.

Plant Location and Investment Factors

A workable fostamatinib site sits inside a small-volume API cluster with phosphorus chemistry experience. Canada hosts Patheon's Whitby plant, which makes the commercial product today. India's Hyderabad, Visakhapatnam & Gujarat clusters offer heterocycle and phosphate chemistry at lower cost. China's Zhejiang and Jiangsu provinces supply fluoropyrimidine and aniline intermediates. Europe and the US host contract manufacturers used for branded supply. A good site needs corrosion-resistant equipment, humidity-controlled rooms & strong solid-state analytical support.

For a fostamatinib project, the first investment decision is timing against patents. Formulation patents run to 2032 in the US, while some earlier prodrug claims expire sooner. The second decision is integration, from intermediates through R406 to finished API. Making R406 in-house captures most of the value, while buying it narrows the work to the prodrug step. Product range, from one molecule to a set of low-volume APIs, is the third decision. A stand-alone fostamatinib line cannot fill a plant. It fits best alongside other low-volume kinase inhibitors and phosphate prodrugs.

Major Fostamatinib Producing Regions

Canada hosts the commercial manufacturing site, through Patheon in Whitby, Ontario. The US holds the originator business, with Rigel based in South San Francisco. Spain hosts Grifols, which markets the product across Europe and neighboring regions. India supplies intermediates and is the likely source of future generic API. China supplies 5-fluorouracil, trimethoxyaniline, and other building blocks at low cost. Research suppliers in the US, Europe & China sell the prodrug and R406 for laboratory work.

Key Fostamatinib Producers

Rigel Pharmaceuticals

• South San Francisco company that developed fostamatinib and markets Tavalisse in the US.
• Reported Tavalisse sales of about 159 million dollars last year, a rise of 52%.
• Competes on first-in-class SYK inhibition & a differentiated mechanism in immune thrombocytopenia.
• Holds formulation patents running to 2032 and earlier prodrug patents.

Patheon

• Contract development and manufacturing business within Thermo Fisher Scientific.
• Makes the commercial fostamatinib product at its Whitby site in Ontario, Canada.
• Competes on regulated-market manufacturing, scale-up skill & quality systems.
• Named on the US label as the manufacturing site.

Grifols

• Spanish healthcare group with a strong hematology and plasma business.
• Markets the product as Tavlesse in Europe, Turkey, the Middle East, North Africa & Russia.
• Competes on hematology reach, hospital access & tender experience in those markets.
• Licensed the product from Rigel and pays tiered royalties.

MedChemExpress

• Supplier of bioactive compounds and inhibitors for research.
• Sells fostamatinib disodium hexahydrate and R406 for laboratory use.
• Competes on catalog breadth, price & fast delivery through distributors.
• Serves kinase biology and platelet research groups.

Selleck Chemicals

• Supplier of inhibitors and screening compounds for drug discovery.
• Lists the hexahydrate salt with published protocols and solubility data.
• Competes on datasheets, protocol support & screening libraries.
• Supplies academic and industrial research laboratories.

Indian Generic API Makers

• Firms in Hyderabad, Gujarat, and elsewhere developing fostamatinib processes.
• Several generic applications have reportedly been filed in the US.
• Compete on low-cost heterocycle chemistry, scale & early filings.
• Likely the first source of generic material once patents allow.